Entering text into the input field will update the search result below

Seelos gets acknowledgement letter from Australian regulator for Alzheimer's study

Mar. 08, 2022 11:45 AM ETSeelos Therapeutics, Inc. (SEEL)By: Ravikash, SA News Editor

Brain problems. Parkinson and alzheimer desease. Mental health. Stroke, synapses and neurnons interaction

Naeblys/iStock via Getty Images

  • Seelos Therapeutics (NASDAQ:SEEL) received an acknowledgement letter of a Clinical Trial Notification (CTN) from the Australian Government Department of Health Therapeutic Goods Administration (TGA) for a pilot study of SLS-005 to treat patients with Alzheimer's disease.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.